ESR1 and breast cancer: The ATAC study involved postmenopausal women with early ER+ BC and compared the effects of an adjuvant, Anastrozole-based therapy with Tamoxifen-based treatment and demonstrated that BC patients treated with Anastrozole had lower relapse rates than those in the Tamoxifen group.